Author Archives: admin


Stem Cell Clinic > Articles by: admin

The Oncology Institute Extends Its Reach to Serve an Additional 180,000 Patients Through New Contracts and Acquisitions – Yahoo Finance

By Stem Cell Clinic

The Oncology Institute of Hope and Innovation (TOI), the largest community oncology practice on the West Coast, announced today that it has agreed to care for an additional 180,000 patients through new contracts, strategic partnerships, and practice acquisitions.

"TOIs steadfast commitment is to deliver on the promise of value-based care," shared Brad Hively, TOI CEO. "We are excited to enter into partnerships with best-in-class payors and providers, utilizing the skills of our vast network of physicians and years of experience to solve the most pressing challenges around cancer care today."

TOI recently entered into three new value-based contracts extending its reach to Los Angeles, Las Vegas, and southern Californias high desert and mountain communities.

In May, TOI acquired the practice of Dr. Manuel Zevallos, a longstanding and well-respected oncologist in Lynwood, CA. "Joining TOI was a natural fit for my practice," shared Dr. Zevallos. "We share the same evidence-based, patient-first approach." Dr. Zevallos is now practicing from TOIs Lynwood clinic, where he will continuing caring for his patients.

About The Oncology Institute of Hope and Innovation

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is the largest community oncology practice on the west coast, and the nations leading value-based oncology services platform. TOI employs 75 physicians and mid-levels in 40 clinic locations, with over 500 total employees helping to deliver cutting edge, evidence-based cancer care to a population of over 1 million patients. TOI brings comprehensive, integrated cancer care into community settings, including Clinical Trials, Palliative Care programs, Stem Cell Transplants, Transfusions, and other care delivery models more traditionally associated with tertiary care settings. For more information visit http://www.theoncologyinstitute.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005221/en/

Contacts

Julie Korinke Senior Manager, Marketing 562.735.3226 x.88806 juliekorinke@theoncologyinstitute.com

Read the rest here:
The Oncology Institute Extends Its Reach to Serve an Additional 180,000 Patients Through New Contracts and Acquisitions - Yahoo Finance

Impact of COVID-19 on Osteonecrosis Treatment Market Emerging Growth And Forecast to 2027 | Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co…

By Stem Cell Treatment

A new business intelligence report released by CMI with title Global Osteonecrosis Treatment Market Research Report 2019-2027 is designed covering micro level of analysis by manufacturers and key business segments. The Global Osteonecrosis Treatment Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities,

Whats keeping Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities, Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by CMI

To learn more about this report, request a samplecopy:https://www.coherentmarketinsights.com/insight/request-sample/1490

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Market Overview of Global Osteonecrosis Treatment

If you are involved in the Global Osteonecrosis Treatment industry or aim to be, then this study will provide you inclusive point of view. Its vital you keep your market knowledge up to date segmented by Applications and major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market.

Furthermore, the years considered for the study are as follows:

Historical year 2014 2018

Base year 2019

Forecast period** 2019 to 2027 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Detailed Segmentation:

By Drug ClassNon-steroidal anti-inflammatory drugs (NSAIDS)Anti-coagulantOther drugsBy Distribution ChannelsHospitals pharmaciesRetail pharmaciesOnline pharmacies

Top Players in the Market are: Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities,

(*Note: Other Players can be added per Request)

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

[**NOTE: Enquiry before Buying option enables you to share your queries, in advance to procure the report. Kindly fill the enquiry form, and one of our consultants would get in touch with you to discuss the queries and would address them.]

Else place an Inquire before Purchase Global Osteonecrosis Treatment Market Size, Share, Growth, and Forecast 2027 @https://www.coherentmarketinsights.com/insight/request-customization/1490

Important Features that are under offering & key highlights of the report:

Detailed overview of Osteonecrosis Treatment market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Osteonecrosis Treatment market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Osteonecrosis Treatment market performance

Market players information to sustain and enhance their footprint

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/1490

Major Highlights of TOC:

Chapter One: Global Osteonecrosis Treatment Market Industry Overview

1.1 Osteonecrosis Treatment Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 Osteonecrosis Treatment Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: Global Osteonecrosis Treatment Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global Osteonecrosis Treatment Market Size by Demand

2.3 Global Osteonecrosis Treatment Market Forecast by Demand

Chapter Three: Global Osteonecrosis Treatment Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2 Osteonecrosis Treatment Market Size by Type

3.3 Osteonecrosis Treatment Market Forecast by Type

Chapter Four: Major Region of Osteonecrosis Treatment Market

4.1 Global Osteonecrosis Treatment Sales

4.2 Global Osteonecrosis Treatment Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Key questions answered

o Who are the Leading key players and what are their Key Business plans in the Global Osteonecrosis Treatment market?

o What are the key concerns of the five forces analysis of the Global Osteonecrosis Treatment market?

o What are different prospects and threats faced by the dealers in the Global Osteonecrosis Treatment market?

o What are the strengths and weaknesses of the key vendors?

Need a discount?

Request discount for this report @https://www.coherentmarketinsights.com/insight/request-discount/1490

Note: *The discount is offered on the Standard Price of the report.an

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact US

Mr.Shah Phone: US +1-206-701-6702/UK +44-020 8133 4027 [emailprotected]

Go here to read the rest:
Impact of COVID-19 on Osteonecrosis Treatment Market Emerging Growth And Forecast to 2027 | Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co...

Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee…

By Platelet Rich Plasma Injections

Objective:The objective of this study was to compare platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived mesenchymal stem cell (MSC) injections in the treatment of osteoarthritis (OA) of the knee using functional scores.

Methods:A total of 89 patients with painful knee OA were included in this study. Patients were assigned to one of the 3 treatments according to severity of OA as indicated by symptoms and radiography to PRP (stage I), BMAC (stage II), or adipose-derived MSC (stage III). Clinical assessment was performed using the Knee Society Score, which combines the Knee Score, based on the clinical parameters, and the Functional Score, and IKDC score. Surveys were completed at preoperative and at 90, 180, and 265 days postoperative. The follow-up responses were compared with baseline and between treatment groups.

Results:Treatment with PRP, BMAC, and adipose-derived MSC included 29 (32.6%), 27 (30.3%), and 33 (37.1%) patients, respectively. For the total group, median age was 61 years (range: 22-84 years). Score values were comparable among treatment groups at baseline. Statistically significant improvement was observed in the 3 groups according to the 3 scores at all time points during follow-up compared with baseline. No difference was found among treatment type.

Conclusions:Our findings support previous reports and encourage further research on the use of these cost-effective treatments for OA of the knee.

Keywords:Platelet-rich plasma; adipose-derived mesenchymal stem cell; bone marrow aspirate concentrate; knee; osteoarthritis.

See the original post:
Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee...

Post COVID 19 Pandemic Global Canine Stem Cell Therapy Market Research Report 2020 Top Players Include, VETSTEM BIOPHARMA, Cell Therapy Sciences,…

By Stem Cell Clinics

Global Canine Stem Cell Therapy Market analysis 2015-2027, is a research report that has been compiled by studying and understanding all the factors that impact the market in a positive as well as negative manner. Some of the prime factors taken into consideration are: various rudiments driving the market, future opportunities, restraints, regional analysis, various types & applications, Covid-19 impact analysis and key market players of the Canine Stem Cell Therapy market. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Download Report from: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

Global Canine Stem Cell Therapy Market: Product analysis: Allogeneic Stem Cells, Autologous Stem cells

Global Canine Stem Cell Therapy Market: Application analysis: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

Major Market Players with an in-depth analysis: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet

The research is presented in such a way that it consists of all the graphical representations, pie charts and various other diagrammatic representations of all the factors that are used for the research. Canine Stem Cell Therapy market research report also provides information on how the industry is anticipated to provide a highly competitive analysis globally, revenues generated by the industry and increased competitiveness and expansions among various market players/companies.

Get A Free Sample of Canine Stem Cell Therapy Market Report: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report

The Canine Stem Cell Therapy industry is projected in assembling information regarding dynamic approximations and also listings of a profitable progression rate annually in the expected duration according to a recent & latest study. The latest Coronavirus pandemic impact along with graphical presentations and recovery analysis is included in the Canine Stem Cell Therapy research report. The research report also consists of all the latest innovations, technologies and systems implemented in the Canine Stem Cell Therapy industries.

Various factors with all the necessary limitations, expenditure/cost figures, consumer behaviour, supply chain, government policies and all the information related to the market have been included in the Canine Stem Cell Therapy Market report. The research report also provides light on various companies & their competitors, market size & share, revenue, forecast analysis and all the information regarding the Canine Stem Cell Therapy Market.

Checkout Inquiry for Buying or Customization of Report: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report.

Canine Stem Cell Therapy Market research report provides an in-depth analysis of the entire market scenario starting from the basics which is the market introduction till the industry functioning and its position in the market as well as all the projects and latest introductions & implementations of various products. The research study has been assembled by understanding and combining various analysis of regions globally & companies and all necessary graphs and tables that bring the theory into an exact representation through numerical values and standard tables.

The global estimations of the market value, market information/definition, classifications of all the types & applications, overall threats & dips that can be assumed and many other factors which consist the overall market scenario and its happening globally along with the forthcoming years are compiled in the Canine Stem Cell Therapy market research report. Hence this report can serve as a handbook/model for the enterprises/players interested in the Canine Stem Cell Therapy Market as it consists all the information regarding the Canine Stem Cell Therapy market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here> Download Sample Report of Canine Stem Cell Therapy Market Report 2020 (Coronavirus Impact Analysis on Canine Stem Cell Therapy Market)

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19. (*If you have any special requirements, please let us know and we will offer you the report as you want.)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market. Contact Us: +1-312-376-8303 Email: nicolas.shaw@cognitivemarketresearch.com Web: https://www.cognitivemarketresearch.com/

**********Download the Entire Report************************************************* https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

View post:
Post COVID 19 Pandemic Global Canine Stem Cell Therapy Market Research Report 2020 Top Players Include, VETSTEM BIOPHARMA, Cell Therapy Sciences,...

Can banking your stem cells prevent aging? | Well+Good

By Adult Stem Cells

Ugggghh, getting old sucks!Its something you hear all the time, right? From a 31-year-old, suddenly unable to have two glasses of wine without waking up hungover the next day. A 43-year-old with a bum knee. A 65-year-old who cant remember where she put her keys. And on. And on. And on.

As conventional wisdomhas it, the effects of aging are non-negotiable. Plus, people are living longer than ever, which potentially means more years spent in less-than-optimal condition. But proponents of a new technologystem-cell bankingclaim getting older doesnt have to come with the irreversible downward health spiral weve all been conditioned to expect. Their claim: Storing and eventually re-injecting your own adult stem cells may help your body heal the first signs of age-related disease down the line, keeping you feeling vital longer.

Sounds intriguingbut is it legit?

Heres the deal: Stem cellsare unspecialized cellsthat have the potential to multiply and grow into many different types of cells throughout the body, from bone to muscle to neuron and beyond. By extracting and freezing these repair cells from your own bodybanking them, essentiallythe idea is that when your health starts to decline, you can have them reinserted into your body right at the site of the problem. If you start suffering from arthritis, for example, your stored stem cells would be inserted into your joints so healthy cells will multiply and take over, theoretically eliminating your pain.

One such stem-cell preservation company isForever Labs, which is currently working with physicians in Los Angeles, New York, Miami, Boston, Washington, DC, and more.Forever Labs was born out of our own mid-life crises, says strategic growth expert Steve Clausnitzer, who co-founded the biz with friend and longtime stem-cell researcher Mark Katakowski, PhD.Three years ago, I was turning 40, and I said to Steve, Im convinced that I want to have my young cells later in life, Katakowski says. And he said, You know what? Id like to have that too.

Related Stories

{{ truncate(post.title, 18) }}

Those young cells they were talking about are, of course, stem cells. Doctors are already using these to help the body heal, taking healthy stem cells from a strong part of the body and immediately transplanting them to whatever area new cells are needed. Orthopedic surgeons and sports medicine doctors use bone marrow-derived stem cells to treat injuries, including joint issues and musculoskeletal problems. Theyre regularly used for skin graftsand forcancer patients, replacing blood-formingcellsdestroyed by chemo or radiation.

Armin Tehrany, MD, founder of Manhattan Orthopedic Care(who is unaffiliated with Forever Labs), sees stem-cell therapy as an effective form of treatmentat least in his field of medicinealthough he admits scientists arent exactly sure how or why it works. There are theories that what [stem cells] do is attach to the bodys actual tissue and potentially change the tissue turning those cells on so they become what theyre supposed to be, as opposed to being degenerated part of the tissue, he says.

Banking yourself basically creates a pool of young biology that doesnt experience the wear and tear of life. Steve Clausnitzer, Forever Labs cofounder

Yet, as Katakowski will tell you, one of the sad truths about stem cells is that they lose function as they age. For 17 years, Id been working with bone-marrow stem cells developing treatment for stroke and other neural injuries and diseases, learning firsthand the therapeutic value of the cells, but also that the number of cells and their efficacy is less with age, he explains.

Thats where stem cell banking comes in. Extracting them from your bone marrow or fat stores and cryogenically freezing them while theyre still young and strong is an entirely new concept. (In fact, Forever Labs is the first company thats set on using stem cells to extend human healthspans.) But that may be about to change. Theres been an explosion of clinical application of this knowledgea couple hundred clinical studies at last count,Katakowski says.

Why bank your own stem cells, as opposed to, say, getting them from a younger donor? The short answer is that if you want to replace tissue, you need your own cells, Katakowski says. There is some evidence that you can get some acute benefit using someone elses, but its a short kind of benefit because cells dont stick around. Your body finds them and weeds them out. (Its similar to the way bodies sometimes reject a transplanted organthat means theres no bank-one-for-the-whole-family type of deal.)

Katakowski believes the best time to bank stem cells is between the ages of 20 and 40. That said, he still advises older people to do it, toohis mother banked hers at 70. Dr. Tehrany says its more important to consider your health than actual age when considering any type of stem-cell therapy. Someone can be 75, butphysiologically and genetically be 55, he says. [Conversely,] if someones overall health is declining, its safe to say their stem cell functionality is declining too.

So lets say you buy into this whole freezing-your-stem-cells thing. When, exactly, would you ask for them back? According to Katakowski and Clausnitzer, the time to use them is when you start experiencing undesirable health impacts brought on by aging. This can be caused by something sudden, like having a stroke, or something you notice gradually, like a slow decline in memory. At that point, a doctor would inject your stored stem cells back into the affected body part. (Or partsbecause, lets be honest, aging is a full-body kind of deal.)In theory, the stem cells would then help the not-so-healthy tissue regenerate and become more vital.

Emphasis on the theory part. Since the technology is still so new, its actual success rate is still very much TBD. While Forever Labs has undertaken many encouraging studies with mice, the companys human studiesmore than 700 of themare still underway, and it will take years to see the long-term effects. Dr. Tehrany affirms that this is cutting-edge stuff, and the scientific backup just isnt there yet. But that doesnt mean hes ruling out the stem-cell banking concept. Based on how successful stem cells are as a treatment, I do think its important to respect and value the potential of them as a preventative, he says.

Theres also the lingering thought that maybe youll get lucky and age without any problems at all. Then, wouldnt it be a huge waste of money to pay for decades of stem-cell freezing? (At $2,500 for the procedure and $300 a year for storage, it isnt cheap.) After all, theres tons of emerging research that indicates a healthy diet and regular exercisecan go a long way in preventing age-related declineand those are basically free.(Ah, the boring, yet sound advice thats been preached for decades.)

Clausnitzer personally believes its not wise to play the odds. Theres a lot of evidence that as you get into middle age, all this damage accrues in your cells and a lot of that is irreversible, such as DNA mutations, Clausnitzer says. Banking yourself basically creates a pool of young biology that doesnt experience the wear and tear of life. So what you bank is kind of like the seeds that you can use to grow many, many of your own young stem cells to treat yourself.

Ultimately, no so-called illness-proofing option comes with any guarantees, making the choice a totally personal one. But it does raise the question: If youre 90 years old, but your cells are only 40, how old are you really?

Speaking of longevity, this is the type of exercise thatll add years to your life. Having these personality traits helps, too.

Read more:
Can banking your stem cells prevent aging? | Well+Good

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab – BioSpace

By Stem Cell Treatment

SOMERSET, N.J. & BURLINGAME, Calif.--(BUSINESS WIRE)-- Catalent and Humanigen, Inc. (HGEN) (Humanigen) today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigens proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005256/en/

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies and consumer health products. Humanigen is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys lead therapeutic candidate.

Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients with severe and critical COVID-19 pneumonia, the majority of whom showed rapid recovery and hospital discharge. A Phase 3 study is currently underway evaluating hospitalized COVID-19 patients.

Based on lenzilumabs promising clinical data, we are pleased to expand our relationship with Catalent to solidify our ability to manufacture and supply lenzilumab, commented Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen. If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most.

Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials, commented Karen Flynn, President of Catalent Biologics and Chief Commercial Officer. The experience we already have with lenzilumab, and our OneBio integrated offering from development to supply, make Catalent uniquely suited to support Humanigen in the journey to make this promising therapy available to COVID-19 patients as soon as possible following receipt of regulatory approvals.

To date, Catalent Biologics has provided early-stage development and clinical cGMP drug substance manufacturing for lenzilumab at its facility in Madison, Wisconsin to support Humanigens ongoing clinical trials across various disease categories. Under the expanded partnership, Catalent is also providing clinical supply support for Humanigens Phase 3 potential registration study in COVID-19 from its Philadelphia facility.

Lenzilumab was originally manufactured in Catalents Madison facility using Catalent Biologics proprietary GPEx cell line development technology. As part of the expanded partnership, Catalent intends to provide additional drug substance clinical supply for Humanigens clinical trials, Expanded Access Program (EAP), as well as additional late-stage development and clinical and potential commercial drug substance manufacturing and vial filling at its Madison and Bloomington, Indiana, sites.

Catalent Biologics Madison facility provides development and drug substance manufacturing, including GPEx cell line development, process development, process validation, formulation development, and clinical and commercial cGMP manufacturing. Its Bloomington facility has deep expertise in sterile formulation, with drug substance development and manufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges as well as primary and secondary packaging.

Catalents OneBio Suite is an integrated solution for the development, manufacturing, and supply of biologic drugs. Launched in May 2019, the suite of offerings is designed to integrate activities and accelerate timelines, reduce risk and simplify development with a single contract, program manager, and development timeline from cell line development to supply, with harmonized quality systems.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

About Catalent Biologics

Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.

Humanigens Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase III study and the potential future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe and critical COVID-19 infections or to be approved by FDA for such use or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005256/en/

Visit link:
Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab - BioSpace

Study: Oxygen therapy improves cognitive function in seniors – Mirage News

By Stem Cell Treatment

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, together with Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University announced that, for the first time, in humans, a peer-reviewed study has demonstrated that hyperbaric oxygen therapy (HBOT) can significantly enhance the cognitive performance of healthy older adults.

The main areas of improvement were attention, information processing speed, executive function, in addition to the global cognitive function, all of which typically decline with age. Moreover, there was a significant correlation between the cognitive changes and improved cerebral blood flow in specific brain locations.

The study was published on July 15th, 2020 in the peer reviewed journal Aging, entitled: Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.

Professor Shai Efrati, Head of the Sagol Center for Hyperbaric Medicine and Research, and Head of Research & Development at Shamir Medical Center, and an Associate Professor at Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University, and Dr. Amir Hadanny, the Sagol Center for Hyperbaric Medicine and Research, designed the study based on a unique HBOT protocol developed at the Sagol Center over the past 10 years. The randomized controlled clinical trial included 63 healthy adults (>64) who underwent either HBOT (n=33) or a control period (n=30) for three months. The studys primary endpoint included a change in general cognitive function measured by a standardized comprehensive battery of computerized cognitive assessments before and after the intervention or control. Cerebral blood flow (CBF) was evaluated by a novel magnetic resonance imaging technique for brain perfusion.

Age-related cognitive and functional decline has become a significant concern in the Western world. Major research efforts around the world are focused on improving the cognitive performance of the so-called normal aging population, said Prof. Efrati. In our study, for the first time in humans, we have found an effective and safe medical intervention that can address this unwanted consequence of our age-related deterioration.

Over years of research, we have developed an advanced understanding of HBOTs ability to restore brain function. In the past, we have demonstrated HBOTs potential to improve/treat brain injuries such as stroke, traumatic brain injury and anoxic brain injury (due to sustained lack of oxygen supply) by increasing brain blood flow and metabolism, explained Dr. Amir Hadanny. This landmark research could have a far-reaching impact on the way we view the aging process and the ability to treat its symptoms.

During HBOT, the patient breaths in pure oxygen in a pressurized chamber where the air pressure is increased to twice that of normal air. This process increases oxygen solubility in the blood that travels throughout the body. The added oxygen stimulates the release of growth factors and stem cells, which promote healing. HBOT has been applied worldwide mostly to treat chronic non-healing wounds.

There is a growing body of evidence on the regenerative effects of HBOT. The researchers have demonstrated that the combined action of delivering high levels of oxygen (hyperoxia) and pressure (hyperbaric environment), leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in restored and enhanced tissue metabolism. Moreover, these targeted genes induce stem cell proliferation, reduce inflammation and induce generation of new blood vessels and tissue repair mechanisms.

The occlusion of small blood vessels, similar to the occlusions which may develop in the pipes of an aging home, is a dominant element in the human aging process. This led us to speculate that HBOT may affect brain performance of the aging population, Prof. Efrati explained. We found that HBOT induced a significant increase in brain blood flow, which correlated with cognitive improvement, confirming our theory. One can conjecture that similar beneficial effect of HBOT can be induced in other organs of the aging body. These will be investigated in our upcoming research.

The research group leader, Professor Shai Efrati, who serves as director of The Sagol Center for Hyperbaric Medicine and Research, and is an Associate Professor at Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University, also disclosed his role with Aviv Scientific LTD, which has developed a comprehensive program that includes HBOT treatment, cognitive and physical training and nutritional coaching, to enhance brain and body performance of aging adults based on the Sagol HBOT protocol at Aviv Clinics. Prof. Efrati serves as Chair of Aviv Scientifics Medical Advisory Board.

Continued here:
Study: Oxygen therapy improves cognitive function in seniors - Mirage News

Nebraska AG files lawsuit against Omaha stem cell clinic – Lincoln Journal Star

By Stem Cell Clinics

Nebraska Attorney General Doug Peterson on Thursday filed a lawsuit against an Omaha-based stem cell clinic.

The lawsuit, filed in Douglas County District Court, alleges that the Regenerative Medicine & Anti-Aging Institute of Omaha and its owners,Travis and Emily Autor, made more than $2 million by making deceptive and misleading statements to consumers regarding the ability of their stem cell therapy to treat specific diseases and health conditions.

The lawsuit also alleges the clinic misrepresented that stem cell therapy is safe and that larger doses are more effective, without possessing the necessary evidence to make these types of claims.

It seeks to stop the clinic from making deceptive and misleading claims regarding its treatments, to refund money to patients and to pay an undetermined amount of civil penalties.

According to Peterson, the Autors operate a network of companies across the country that advertise and sell stem cell therapy directly to consumers, with clinics also located in Arizona, Florida, Idaho, Montana, Vermont, Virginia and Washington.

Though the Food and Drug Administration has noted stem cells' potential to treat and cure some diseases and medical conditions, the therapy is not FDA-approved. In September, the FDA warned consumers that the unapproved use of stem cell treatments can be particularly unsafe, and may lead to adverse reactions, such as the failure of cells to function as expected and tumor growth.

The rest is here:
Nebraska AG files lawsuit against Omaha stem cell clinic - Lincoln Journal Star

The Oncology Institute Extends Its Reach to Serve an Additional 180000 Patients Through New Contracts and Acquisitions – Business Wire

By Stem Cell Clinic

CERRITOS, Calif.--(BUSINESS WIRE)--The Oncology Institute of Hope and Innovation (TOI), the largest community oncology practice on the West Coast, announced today that it has agreed to care for an additional 180,000 patients through new contracts, strategic partnerships, and practice acquisitions.

TOIs steadfast commitment is to deliver on the promise of value-based care, shared Brad Hively, TOI CEO. We are excited to enter into partnerships with best-in-class payors and providers, utilizing the skills of our vast network of physicians and years of experience to solve the most pressing challenges around cancer care today.

TOI recently entered into three new value-based contracts extending its reach to Los Angeles, Las Vegas, and southern Californias high desert and mountain communities.

In May, TOI acquired the practice of Dr. Manuel Zevallos, a longstanding and well-respected oncologist in Lynwood, CA. Joining TOI was a natural fit for my practice, shared Dr. Zevallos. We share the same evidence-based, patient-first approach. Dr. Zevallos is now practicing from TOIs Lynwood clinic, where he will continuing caring for his patients.

About The Oncology Institute of Hope and Innovation

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is the largest community oncology practice on the west coast, and the nations leading value-based oncology services platform. TOI employs 75 physicians and mid-levels in 40 clinic locations, with over 500 total employees helping to deliver cutting edge, evidence-based cancer care to a population of over 1 million patients. TOI brings comprehensive, integrated cancer care into community settings, including Clinical Trials, Palliative Care programs, Stem Cell Transplants, Transfusions, and other care delivery models more traditionally associated with tertiary care settings. For more information visit http://www.theoncologyinstitute.com.

Read the original here:
The Oncology Institute Extends Its Reach to Serve an Additional 180000 Patients Through New Contracts and Acquisitions - Business Wire

Why is this nebula shaped like a butterfly? – Massive Science

By Stem Cell Doctors

Eight years ago, I was packing my home and entire life in Mexico to move to the US to pursue a PhD in Ecology and Evolutionary Biology at the University of California-Irvine. Those were easier times, although it did not seem like it at the time. I spent a few months worth of income to pay for paperwork to apply for an F-1 student visa, and to pay for other documents to enroll as a graduate student. This was after I dedicated months to emailing professors everywhere in the US, hoping that one of them would reply to my email and would invite me to apply to join their lab. It was also after spending time and money paying for standardized tests, official document translations, and application fees. It was a one-and-a-half-year process but in July 2012, I was finally moving to the USA to pursue my PhD. It was a dream come true.

It was also a dream come true for the University of California because I had a full scholarship from my home country that paid for the entirety of my international tuition and fees, which were around $35,000 per year. My scholarship allowed me to pursue my PhD in the USA, and to UC Irvine it provided basically free labor as well as prestige.

I paid taxes and did all of the typical graduate student responsibilities. I also dedicated a lot of my time to doing outreach to bring science to underserved communities around Orange County and Southern California. By the time I graduated in 2017, I was a stellar student, with three publications with UC Irvine's name on them. I co-organized summer science camps for middle school girls that brought money and a good reputation to my university and program. I mentored students of all ages. I was a good citizen of my program, of my university, and of Orange County.

Like me, most international students leave their families and everything that they are comfortable with to pursue the dream of graduate school. They bring with them the hope of being welcomed and treated fairly by their American peers. I have experienced this, but I am one of the lucky ones.

It is no secret that international students and postdocs will withstand abuse and other injustices just so they can keep their visa, which is always tied to their university. Many universities receive international students without having a system to deal with the unique challenges that international students face, such as having no credit history, which complicates finding a place to live and leaves international students vulnerable to landlord abuse. Many international students are people of color, and universities, especially predominantly white institutions, do not have resources to ensure safety of these students within the university and in the community at large.

These challenges are further complicated due to a lack of community and support. Making friends in the US, especially if you are coming from Global South countries and/or non-Westernized countries, is extremely challenging. Many times, I have seen how western Europeans, Australians, and Canadians are rapidly accepted in the local community, while many Latinx, Asians, and Middle-Easterners are not.

There are over one million international students in the US. The ICE Student Ban may no longer be a threat, but universities still need to change how they handle international students. We are people too, but many universities have historically valued us only by the amount of money we bring. We improve higher education not only by the money that we bring, but by our unique perspectives, our research productivity, and our willingness to give back to American society.

See the article here:
Why is this nebula shaped like a butterfly? - Massive Science

→←